Dualsystems Biotech AG Press Release
Dualsystems Biotech partners with IBR Inc. to validate the workflow of the CaptiRec Technology
Schlieren, Switzerland, January 2014: – Dualsystems Biotech AG has announced it will collaborate with another Swiss laboratory, Institute for Biopharmaceutical Research (IBR Inc.) to validate the CaptiRec Triceps/Ligand Receptor Capture Technology. This technology is used to identify the Cell Membrane Receptors on Living Cells.
The partnership will combine the respective strengths of Dualsystems, a leading service provider for protein interaction at the cell membrane and IBR Inc., a GLP-compliant contract research organization specializing in cell-based assays
Video interview of CaptiRec Services, ligand-receptor capture technology (LRC) with Dr. Paul Helbling, the new management of Dualsystems Biotech AG.
Dualsystems Biotech closes Licensing Agreement with ETH Zurich on Ligand Receptor Capture (LRC) technology
Dualsystems Biotech has licensed an innovative technology to discover cell-surface receptors for a vast range of ligands of interest. LRC is centered around an innovative trifunctional chemoproteomic reagent named TriCEPS™, which enables the unbiased identification of cell surface receptors for many types of ligands, such as peptides, proteins, antibodies, engineered affinity binders or viruses. Receptor capture takes place under near-physiological conditions on native tissues and cells, without the need for genetic manipulations. Read more
LRC TriCEPS Service
Dualsystems Biotech AG
Dr. Paul Helbling
phone +41 44 738 50 00
fax +41 44 738 50 05